




Slide 3 • NCSC 2012, Tina Mi

Slide 1 • NCSC 2012, Tina Müller

Bayer HealthCare







Example Data Set				Example Data Set					ER		
Method	Group	Mean estimate	Confidence interval	p-value	Model estima	Model estimates					
linear model (original) linear model	Treatment	0.87 0.59	(0.73, 1.01) (0.41, 0.77)	0.012	Method	Group	Estimate	Standard Error	Mean	CI	
(logit)	1				linear mode					(0.80, 0.95	
LagDag	Control	0.87	(0.70, 0.95)		(logit) Treatment Control		0.29		(0.41, 0.76) (0.70, 0.95)	
	Treatment	0.59	(0.47, 0.71)		LogReg	Treatment				(0.70, 0.93) (0.47, 0.70)	
 Confiden Transform LogReg p 		t analyzed	Faddin of neovacularized area 0.2 0.4 0.6 0.6 1	•							



Summary & Outlook

Our situation

· Until now: small number of experiments, each of limited sample size

- Logit-normal model:
 - · seems to fit quite well
 - explainable to biologist
 - assumes a 'biological symmetry' between neovascularized and vessel-free area within total cornea area

Bayer HealthCare

Open questions

- Documentation of calculations in SAS® 9.2
- Other link functions more appropriate?
- · Completely different approaches?

Slide 13 • NCSC 2012, Tina Müller

